XGN News and Press, Exagen Inc. From 07/25/23

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before the market open on Monday, August 7, 2023. John Aballi, Exagen’s President and Ch...

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Off...

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43 r d Annual Growth Stock Conference, which takes place June 6-8, 2023, in Chicago at the Loews Chic...

2023-05-15 22:23:02 ET Exagen Inc. (XGN) Q1 2023 Earnings Conference Call May 15, 2023 04:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference ...

2023-05-15 16:09:58 ET Exagen press release ( NASDAQ: XGN ): Q1 GAAP EPS of -$0.44 beats by $0.12 . Revenue of $11.2M (+7.7% Y/Y) beats by $1.8M . We are providing revenue guidance for the second quarter of 2023 in the range of $10.7 million to $11.2 million ...

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023. First Quarter Highlights: Delivered a record 37,312 AVISE &#x...

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impac...

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2023, after the market close on Monday, May 15, 2023. John Aballi, Exagen’s President and Ch...

2023-03-20 19:53:08 ET Exagen Inc. (XGN) Q4 2022 Results Conference Call March 20, 2023 04:30 PM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference C...

2023-03-20 16:10:12 ET Exagen press release ( NASDAQ: XGN ): Q4 GAAP EPS of -$0.83 misses by $0.07 . Revenue of $12.84M (+1.2% Y/Y) beats by $4.14M . Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth qu...